Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
eylea save search
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.0%
H: 0.27%
C: -0.46%
eylea lancet macular injection diabetic
Global EYLEA Drug Market Size to Surpass US$ 14.30 Billion by 2030 | Exhibiting a CAGR of 7.2% : CoherentMI
Published: 2024-01-16 (Crawled : 18:00) - prnewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.26%
H: 0.34%
C: -1.13%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -1.28%
H: 8.19%
C: 6.03%
drug eylea global market
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
Published: 2024-01-03 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 1.23%
H: 2.17%
C: 1.57%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -0.97%
H: 1.53%
C: 0.0%
avt06 eylea candidate biosimilar results study
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
Published: 2023-11-01 (Crawled : 20:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.08%
H: 4.96%
C: 3.4%
eylea macular injection diabetic
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
Published: 2023-10-05 (Crawled : 13:30) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.0%
H: 2.04%
C: 1.98%
eylea macular trial injection results
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
Published: 2023-08-18 (Crawled : 23:00) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
fda eylea macular approved treatment injection diabetic
Regeneron Eyes Earlier FDA Decision on Higher-Dose Eylea
Published: 2023-08-03 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.6%
H: 0.11%
C: 0.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.79%
H: 0.0%
C: 0.0%
fda eylea
Global Eylea Market Sees Impressive Growth with Major Players Regeneron Pharmaceuticals, Bayer AG, and More Expanding Research and Development Efforts
Published: 2023-07-24 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.88%
H: 0.0%
C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.66%
H: 0.43%
C: -1.33%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.64%
H: 1.58%
C: 1.35%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.54%
H: 1.31%
C: 0.92%
eylea research global growth market
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
Published: 2023-05-10 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 0.11%
H: 4.69%
C: 3.77%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -1.04%
H: 1.89%
C: -0.42%
eylea biosimilar commercialization agreement
Regeneron Diversifies Portfolio as Eylea Revenue Takes a Hit
Published: 2023-05-05 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.74%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.81%
H: 0.0%
C: 0.0%
eylea
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 4.4%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.22%
H: 0.83%
C: -0.87%
eylea treatment fda approved injection
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Published: 2023-01-09 (Crawled : 14:00) - biospace.com/
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -5.97%
H: 2.18%
C: -1.82%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.04%
H: 2.17%
C: -7.23%
fyb203 eylea biopharma acquire biosimilar commercial
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection
Published: 2022-10-21 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: -0.06%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.0%
H: 1.74%
C: 1.14%
eylea six injection
EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.15%
H: 1.25%
C: -1.42%
eylea treatment fda review injection
Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales
Published: 2022-08-03 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
covid-19 sales eylea drop antibody dupixent
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
Published: 2022-07-07 (Crawled : 13:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 2.82%
H: 5.72%
C: -18.08%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 0.85%
H: 0.21%
C: -0.21%
avt06 eylea biosimilar study
EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
TEVJF | $12.37 -24.22% 380
|
Health Technology
|
| O: -9.17%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.53%
H: 1.65%
C: 0.01%
eylea fda review injection diabetic
Gentherm President and CEO Phil Eyler Named EY Entrepreneur Of The Year® 2021 Michigan and Northwest Ohio Award Finalist
Published: 2021-06-11 (Crawled : 12:15) - globenewswire.com
THRM | $50.29 -0.38% -0.38% 140K
|
Producer Manufacturing
|
| O: 0.91%
H: 0.66%
C: 0.61%
ceo
NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
Published: 2021-03-30 (Crawled : 00:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.59%
H: 0.36%
C: 0.12%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.42%
H: 0.65%
C: 0.11%
injection trial diabetic diabetes
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.